{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0041429\nAge: 80\nGender: Male\nSample ID: P-0041429-T01-IM6\nGene Panel: IMPACT468\nCancer Type: Prostate Adenocarcinoma\nSample Type: Primary\nTumor Purity: 10.0%\n=============\nDNA Variants:\nGATA1 c.302C>T (p.T101M) - in 57.00% of 227 reads\nKMT2D c.588dup (p.C197Lfs*23) - in 21.00% of 500 reads\nSETD2 c.4813T>A (p.Y1605N) - in 30.00% of 420 reads\nSF3B1 c.3236A>G (p.N1079S) - in 25.00% of 439 reads\nSPOP c.304T>G (p.F102V) - in 26.00% of 374 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nPTEN - PTEN (DELETION)\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Prostate Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Primary\",\n    \"Drug Name\": \"Androgen Deprivation Therapy (ADT) with or without Next-generation Antiandrogens (e.g., Enzalutamide, Abiraterone)\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified; standard first-line therapy for primary prostate cancer\",\n    \"Genomic Features\": \"PTEN deletion (loss of tumor suppressor gene), SPOP mutation (F102V), other mutations may inform prognosis but currently do not alter standard initial treatment\",\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/enzalutamide and https://www.fda.gov/drugs/resources-information-approved-drugs/abiraterone-acetate\"\n  }\n}"
}